Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ
Tytuł pozycji:

IFN-β and multiple sclerosis: cross-talking of immune cells and integration of immunoregulatory networks.

Tytuł :
IFN-β and multiple sclerosis: cross-talking of immune cells and integration of immunoregulatory networks.
Autorzy :
Severa M; Department of Infectious, Parasitic and Immune-mediated Diseases, Istituto Superiore di Sanità, Rome, Italy. Electronic address: .
Rizzo F; Department of Infectious, Parasitic and Immune-mediated Diseases, Istituto Superiore di Sanità, Rome, Italy.
Giacomini E; Department of Infectious, Parasitic and Immune-mediated Diseases, Istituto Superiore di Sanità, Rome, Italy.
Salvetti M; Centre for Experimental Neurological Therapies (CENTERS) - Neurology and Department of Neurosciences, Mental Health and Sensory Organs; Sapienza, University of Rome, S. Andrea Hospital Site, Italy.
Coccia EM; Department of Infectious, Parasitic and Immune-mediated Diseases, Istituto Superiore di Sanità, Rome, Italy. Electronic address: .
Pokaż więcej
Źródło :
Cytokine & growth factor reviews [Cytokine Growth Factor Rev] 2015 Apr; Vol. 26 (2), pp. 229-39. Date of Electronic Publication: 2014 Nov 22.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't; Review
Język :
English
Imprint Name(s) :
Original Publication: Oxford : Elsevier Science, c1996-
MeSH Terms :
Interferon-beta/*therapeutic use
Multiple Sclerosis/*drug therapy
Multiple Sclerosis/*immunology
Antiviral Agents/therapeutic use ; B-Lymphocytes/immunology ; Dendritic Cells/immunology ; Disease Progression ; Humans ; Immunomodulation ; Interferon-beta/immunology ; Monocytes/immunology
Contributed Indexing :
Keywords: Bystander immune regulation; IFN-β therapy; Immune cell subsets; Multiple sclerosis
Substance Nomenclature :
0 (Antiviral Agents)
77238-31-4 (Interferon-beta)
Entry Date(s) :
Date Created: 20141216 Date Completed: 20160119 Latest Revision: 20150406
Update Code :
20210210
DOI :
10.1016/j.cytogfr.2014.11.005
PMID :
25498525
Czasopismo naukowe
Multiple sclerosis (MS) is characterized by autoimmune inflammation affecting the central nervous system and subsequent neurodegeneration. Historically, damage was thought to be mediated exclusively by auto-antigen-activated pro-inflammatory T cells. However, more recently, we are gaining increasing knowledge on the pathogenic role played in MS by B cells, dendritic cells and monocytes. IFN-β therapy was one the first approved therapy for MS for its ability to reduce relapse rate and MRI lesion activity and to significantly decrease risk of disability progression. IFN-β-mediated mechanisms of action, even if not completely understood, mainly rely on its multifaceted pleiotropic effects resulting in sustained anti-inflammatory properties directed toward almost every immune cell type. Here, we will discuss in detail literature data characterizing the pathogenic activity of the different immune cell subsets involved in MS pathogenesis and how IFN-β therapy regulates their function by modulating bystander responses. We believe that the effectiveness of this drug in MS treatment, even if in use for a long time, can unveil new insights on this disease and still teach a lesson to researchers in the MS field.
(Copyright © 2014 Elsevier Ltd. All rights reserved.)

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies